Top-selling asthma drugs Serevent and Advair is back in the spotlight
Reuters News Service
LONDON - The safety of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair is back in the spotlight this week as a U.S. regulatory panel meets to consider their safety in children.
Europe's biggest drugmaker said on Monday it remained confident the benefits of its products outweighed any risks.
Concerns about rare and potentially fatal side effects were raised in briefing documents posted by Food and Drug Administration staff ahead of a November 27-29 meeting of the agency's Pediatric Advisory Committee.
There were nine cases of adverse events in children under 16 using Serevent, or salmeterol, in the year following granting of pediatric market exclusivity in March 2006, including five deaths, papers posted on the FDA Web site show:
Serevent, a long-acting beta agonist used to ease breathing, is also included in Advair, Glaxo's biggest product with worldwide sales of 3.3 billion pounds ($6.8 billion) in 2006. U.S. sales accounted for 1.9 billion pounds last year.
It is not the first time that rare adverse events have been reported with Advair and Serevent and industry analysts said the latest regulatory scrutiny would probably not have any immediate impact.
"While the FDA's attention is unwelcome, any formal additional recommendations against use in children that would significantly affect prescribing behavior would seem some way off," analysts at Deutsche Bank said in a note.
The FDA already issued a warning in November 2005 that drugs containing long-acting beta agonists, such as Advair and Serevent, can sometimes paradoxically trigger severe asthma attacks and death.